Related Experiment Video

Updated: May 19, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors

Kein-Leong Yim1

  • 1Velindre Cancer Center, Cardiff, Wales, United Kingdom.

Cancer Management and Research
|August 21, 2012
PubMed

Insights

New treatments targeting the mammalian target of rapamycin (mTOR) pathway show promise for advanced pancreatic neuroendocrine tumors. Everolimus, an mTOR inhibitor, has demonstrated significant benefits in delaying tumor progression for these rare cancers.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Pancreatic neuroendocrine tumors (PNETs) are rare, with most patients diagnosed at advanced stages.
  • Current treatments for metastatic PNETs offer limited efficacy in impeding tumor progression or improving survival.

Purpose of the Study:

  • To review the mechanism of mammalian target of rapamycin (mTOR) inhibition.
  • To trace the clinical evidence supporting mTOR inhibitors for advanced pancreatic neuroendocrine tumors.

Main Methods:

  • Review of recent clinical trials and scientific literature.
  • Focus on the phosphatidylinositol 3-kinase-Akt pathway and mTOR signaling.

Main Results:

  • Mammalian target of rapamycin (mTOR) identified as a key target in tumor proliferation and angiogenesis.
  • Everolimus, a novel mTOR inhibitor, has shown significant benefits in delaying tumor progression in clinical trials.

Conclusions:

  • mTOR inhibitors represent a promising therapeutic strategy for well- to moderately differentiated advanced pancreatic neuroendocrine tumors.
  • Everolimus offers a new avenue for managing metastatic PNETs, improving progression-free survival.
Keywords:
everolimusmTORneuroendocrinepancreaticsignalingtargeted

More Related Videos

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation08:05

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

Published on: June 8, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...